Clomiphene Citrate co-treatment with low dose urinary FSH versus urinary FSH for clomiphene resistant PCOS: Randomized controlled trial

Journal of Assisted Reproduction and Genetics

Volumn 30, Issue 11, 2013, Pages 1477-1485

  Ghanem, Mohamad E ^a,b   Elboghdady, Laila A ^a,b   Hassan, Mohamad ^a,b   Helal, Adel S ^a,b   Gibreel, Ahmed ^b   Houssen, Maha ^c   Shaker, Mohamed E ^d   Bahlol, Ibrahiem ^a,b   Mesbah, Yaser ^b  

^a Mansoura Integrated Fertility Center   (Egypt)

^b MANSOURA UNIVERSITY   (Egypt)

^c DAMANHOUR UNIVERSITY   (Egypt)

^d MANSOURA UNIVERSITY   (Egypt)

Author keywords

Chronic low dose FSH; Clomiphene resistant PCOS; Ovulation induction; PCOS; Randomized controlled trial

Indexed keywords

CLOMIFENE CITRATE; FOLLITROPIN; FOSTIMONE; GONADOTROPIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLOMIPHENE RESISTANT OVARY POLYCYSTIC DISEASE; CONTROLLED STUDY; ENDOMETRIAL THICKNESS; FEMALE; HUMAN; LIVE BIRTH; LOW DRUG DOSE; MAJOR CLINICAL STUDY; OVARY POLYCYSTIC DISEASE; OVULATION; PREGNANCY; PREGNANCY RATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; CLOMIPHENE; DRUG COMBINATIONS; DRUG RESISTANCE; FEMALE; FERTILITY AGENTS, FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; INFERTILITY, FEMALE; OVULATION; OVULATION INDUCTION; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PREGNANCY RATE; YOUNG ADULT;

EID: 84890561877     PISSN: 10580468     EISSN: 15737330     Source Type: Journal    
DOI: 10.1007/s10815-013-0090-2     Document Type: Article

References (29)

1. The Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Consensus on women's health aspects of polycystic ovary syndrome (PCOS). Hum Reprod. 2012;27:14-24.
2. Gianaroli L, Racowsky C, Geraedts J, Cedars M, Makrigiannakis A, Roger L. Best practices of ASRM and ESHRE: a journey through reproductive medicine. Hum Reprod. 2012;27:3365-79.
3. Balen A. Strategies for ovulation induction in the management of anovulatory polycystic ovary syndrome. In: Azziz R, editor. The polycystic ovary syndrome: Current concepts on pathogenesis and clinical care. Springer Science, Business Media, LLC; 2007. p. 99-112.
4. Eijkemans J, Habbema D, Fauser C. Characteristics of the best prognostic evidence: an example on prediction of outcome after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Semin Reprod Med. 2003;1:39-47.
5. Palomba S, Fallo A, Zullo F. Management strategies for ovulation induction in women with PCOS and known clomiphene citrate resistance. Curr Opin Obstet Gynecol. 2009;21:465-73.
6. White M, Polson W, Kiddy D, Sagle P, Watson H, Gilling-Smith C, et al. Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women. J Clin Endocrinol Metab. 1996;81:3821-4.
7. Balasch J, Fabregues F, Creus M, Casamitjana R, Puerto B, Vanrell A. Recombinant human follicle-stimulating hormone for ovulation induction in polycystic ovary syndrome: a prospective, randomized trial of two starting doses in a chronic low-dose step-up protocol. J Assist Reprod Genet. 2000;17:561-5.
8. Homburg R, Hendriks L, König E, Anderson A, Balen H, Brincat M, et al. Clomifene citrate or low-dose FSH for the first-line treatment of infertile women with anovulation associated with polycystic ovary syndrome: a prospective randomized multinational study. Hum Reprod. 2012;27:468-73.
9. Dickey P, Olar T, Taylor N, Curole N, Rye H. Sequential clomiphene citrate and human menopausal gonadotrophin for ovulation induction: comparison to clomiphene citrate alone and human menopausal gonadotrophin alone. Hum Reprod. 1993;8:56-9.
10. Bedaiwy M, Forman R, Mousa A, Al Inany H, Casper F. Cost-effectiveness of aromatase inhibitor co-treatment for controlled ovarian stimulation. Hum Reprod. 2006;22:2838-44.
11. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41-7.
12. Fritz A, Speroff L. In: Frtiz MA, Speroff L, editors. Induction of ovulation in clinical gynecologic endocrinology and infertility. 8th ed. Philadelphia USA: Lippicott Williams; 2011. p. 1293-300.
13. World Health Organization. WHO Laboratory Manual for the Examination of Human Semen and Sperm-Cervical Mucus Interaction. 4th ed. Cambridge, UK: Cambridge University Press; 1999.
14. Trinder P. Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromagen. J Clin Pathol. 1969;22:158-61.
15. Wahlefeld W. Triglyceride: determination after enzymatic hydrolysis. In: Bergmeyer HU, editor. Methods of Enzymatic Analysis. 2 Englishth ed. New York and London: Verlag Chemie Weinhiem and Academic press, Inc; 2000. p. 1831.
16. Assmann G, Schriewer H, Schmitz G, Hagele O. Quantification of high-density-lipoprotien cholesterol by precipitation with phosphotungestic acid/MgCl2. Clin Chem. 1983;29:2026-30.
17. Friedwald T, Levy I, Fredrickson S. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
18. Matthews R, Hosker P, Turner C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-9.
19. Mc Cann D, Kirkish L. Immunoassay. 1985;8:234-6.
20. Liberopoulos N, Mikhailidis P, Elisaf S. Diagnosis and management of the metabolic syndrome in obesity. Obes Rev. 2005;6:283-96.
21. Moran L, Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update. 2009;15:477-88.
22. Homburg R. Clomiphene citrate - end of an era? A mini-review. Hum Reprod. 2005;20:2043-51.
23. Imani B, Eijkemans J, te Velde R, Habbema D, Fauser C. Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J Clin Endocrinol Metab. 1998;83:2361-5.
24. Hamilton-Fairley D, Kiddy D, Watson H, Paterson C, Franks S. Association of moderate obesity with a poor pregnancy outcome in women with polycystic ovary syndrome treated with low dose gonadotrophin. Br J Obstet Gynaecol. 1992;99:128-31.
25. Yarali H, Basaran M, Yigit N, Bukulmez O, Bildirici I. Gonadotropin treatment using the low-dose step-up protocol in patients with clomiphene citrate [CC] resistant polycystic ovary syndrome (PCOS): factors affecting outcome. Fertil Steril. 2001;76:S207-20.
26. Orviet R, Homburg R. Chronic ultra-low dose follicle-stimulating hormone regimen for patients with polycystic ovary syndrome: one click, one follicle, one pregnancy. Fertil Steril. 2009;S1:1533-5.
27. Dale O, Tanbo T, Haug E, Åbyholm T. The impact of insulin resistance on the outcome of ovulation induction with low-dose follicle stimulating hormone in women with polycystic ovary syndrome. Hum Reprod. 1998;13:567-70.
28. Wely V, Bayram N, van der Veen F, Bossuyt M. Predicting ongoing pregnancy following ovulation induction with recombinant FSH in women with polycystic ovary syndrome. Hum Reprod. 2005;20:1827-32.
29. Andersen N, Balen H, Platteau P, Pettersson G, Arce C. Prestimulation parameters predicting live birth in anovulatory WHO Group II patients undergoing ovulation induction with gonadotrophins. Hum Reprod. 2010;25:1988-95.